In the subgroups (except ATRX subgroup), patients in the high-risk group had a significantly worse prognosis, relative to the low-risk group (Fig. 5a, P < 0.05), implicating that the 6-gene risk score can predict the survival status in GBM patients. This evidence concerns the gene ATRX and glioblastoma.